On the road to optimized BTK inhibition in CLL

Abstract

In this issue of Blood, Byrd et al present the results of a pilot phase 1/2 trial assessing acalabrutinib in previously untreated patients with chronic lymphocytic leukemia (CLL).

Keywords

• ibrutinib
• leukemia